May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- Hospital addresses barriers to patient rest, recovery
- Study: Psilocybin therapy reduces depression in frontline clinicians
- Exclusive articles preview OR Business Management Conference sessions
- Study: Surgeries improve survival in young BRCA-positive breast cancer patients
- Study: Advanced recovery room care could reduce long-term postoperative mortality
- FDA designates Class 1 recalls for balloon catheters, radiographic markers
- Orthopedic surgery in 2025: Embracing innovation, preserving autonomy
- Medtronic, Zimmer Biomet challenge Intuitive Surgical’s robotic surgery dominance
- Anthem’s anesthesia time limit policy, reversal sparks new legislation
- Simple procedure or ‘surgery’? Questionable medical billing practices cause confusion
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement